Your browser doesn't support javascript.
loading
NO-dependent vasodilation and deep tumor penetration for cascade-amplified antitumor performance.
Xu, Qing; Chen, Gui; Chen, Guimei; Wu, Hualan; Yang, Yuanyuan; Mai, Ziyi; Sun, Rui; Luan, Ping; Guo, Chaowan; Yu, Meng; Peng, Zhenwei; Yu, Zhiqiang.
Afiliação
  • Xu Q; Guangdong Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, China.
  • Chen G; Guangdong Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, China.
  • Chen G; Guangdong Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, China.
  • Wu H; The First Clinical Medical School, Southern Medical University, Guangzhou 510515, China.
  • Yang Y; Guangdong Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, China.
  • Mai Z; Guangdong Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, China.
  • Sun R; Guangdong Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, China.
  • Luan P; Guangdong Second Provincial General Hospital & Health Science Center, Shenzhen University, Shenzhen 518060, China.
  • Guo C; Guangdong Marubi Biotechnology Co., Ltd. No 92 Banhe Road, Huangpu District, Guangzhou 510700, China.
  • Yu M; Guangdong Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, China. Electronic address: yumeng999@smu.edu.cn.
  • Peng Z; Department of Radiation Oncology, Institute of Precision Medicine, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou 510080, China. Electronic address: pzhenw@mail.sysu.edu.cn.
  • Yu Z; Guangdong Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, China. Electronic address: yuzq@smu.edu.cn.
J Control Release ; 347: 389-399, 2022 07.
Article em En | MEDLINE | ID: mdl-35569586
ABSTRACT
Nonspecific biodistribution and poor permeability of conventional therapeutic agents in solid tumors severely compromised the antitumor efficacy. Herein, we report a cascade tumor therapeutic nanoplatform consisting of docosahexaenoic acid (DHA) and nicorandil (NI), namely DNP, to specifically produce cytotoxic agents in tumor cells as well as dilating blood vessels to increase the intratumoral oxidative stress levels. The DHA embedded in the membrane could generate reactive oxygen species (ROS) meanwhile NI produced nitric oxide (NO) in response to intracellular glutathione (GSH) in tumors. Notably, the two functional species could further react in situ to form a more tumoricidal reactive nitrogen species (RNS), causing selectively cascade amplification of antitumor performance. In addition, NO-induced vasodilation could consequently result in a series of functions, including hypoxia relief and deep tumor transportation. In general, we anticipate that the DNP could show great potential for tumor-specific treatment by selectively producing RNS precursors in response to the interior environment of tumor cells for hypoxia normalization and tumor inhibition.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Vasodilatação / Óxido Nítrico Limite: Humans Idioma: En Revista: J Control Release Assunto da revista: FARMACOLOGIA Ano de publicação: 2022 Tipo de documento: Article País de afiliação: China

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Vasodilatação / Óxido Nítrico Limite: Humans Idioma: En Revista: J Control Release Assunto da revista: FARMACOLOGIA Ano de publicação: 2022 Tipo de documento: Article País de afiliação: China